ArticleJournal of clinical microbiology2004
Genetic bases of the rifampin resistance phenotype in Brucella spp.
Article in Journal of clinical microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.PLoS medicine · 2007Guideline
- Conserved intracellular virulence architecture and focal genomic diversification in sub-Saharan AfricanMicrobiology spectrum · 2026Article
- Molecular Interplay of Brucellosis and Tuberculosis: Insights into Telomere Biology, Oxidative Stress, and Drug Resistance Mechanisms.Diseases (Basel, Switzerland) · 2026Review
- A review on phytochemical and bacteriophage based therapeutic strategies for the management of Brucellosis.Frontiers in veterinary science · 2026Review
- HflX mediates rifampicin resistance inFrontiers in microbiology · 2026Article
- Genomic analysis of Brucella melitensis isolates recovered from humans in south Tunisia over 35 years between 1988 and 2022.BMC microbiology · 2025Article
- Reactivation of hidden-latentAntimicrobial agents and chemotherapy · 2025Article
- The (p)ppGpp synthetase Rsh promotes rifampicin tolerant persister cell formation inFrontiers in microbiology · 2024Article
- Genotype diversity of brucellosis agents isolated from humans and animals in Greece based on whole-genome sequencing.BMC infectious diseases · 2023Article
- Molecular characterization and antimicrobial susceptibility of humanFrontiers in microbiology · 2023Article
- Adaptation ofMicroorganisms · 2022Article
- Antibiotic persistence of intracellular Brucella abortus.PLoS neglected tropical diseases · 2022Article
- Identifying potential natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach.PLoS neglected tropical diseases · 2022Article
- Whole-Genome Sequencing for Tracing the Genetic Diversity ofPathogens (Basel, Switzerland) · 2021Article
- Proteomics of Brucella.Proteomes · 2020Review
- Identification, Genotyping and Antimicrobial Susceptibility Testing ofMicroorganisms · 2019Article
- Sustained antigen release polyanhydride-based vaccine platform for immunization against bovine brucellosis.Heliyon · 2019Article
- Bifidobacterium adolescentis is intrinsically resistant to antitubercular drugs.Scientific reports · 2018Article
- Antimicrobial Resistance inMicrobiology spectrum · 2018Review
- Whole-genome sequencing and antimicrobial resistance in Brucella melitensis from a Norwegian perspective.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rifampin is one of the most potent and broad-spectrum antibiotics against bacterial pathogens. Its bactericidal activity is due to its ability to bind to the beta subunit of the DNA-dependent RNA polymerase encoded by the rpoB gene. Mutations of the rpoB gene have been characterized in rifampin-resistant (Rif(r)) strains of Escherichia coli and Mycobacterium tuberculosis. The genetic bases of Rif(r) in Brucella spp. are still unknown. In the present study, the nucleotide sequences of the rpoB gene of the Rif(r) vaccine strain Brucella abortus RB51 and of 20 Rif(r) clones derived in our laboratory from two Brucella melitensis isolates were determined. These sequences were then compared to those of the respective rifampin-susceptible (Rif(s)) parental strains and to the published B. melitensis strain 16M. All Rif(r) strains carried one or more missense mutations mapping in two regions of the rpoB gene. These two "hot" regions were investigated in eight additional Rif(r) Brucella laboratory mutants and in 20 reference Rif(s) Brucella strains. rpoB mutations were found in all Rif(r) mutants. In contrast, no missense mutations were found in any analyzed Rif(s) strains. Our results represent the first from a study of the molecular characterization of rpoB mutations in resistant Brucella strains and provide an additional proof of the association of specific rpoB mutations with the development of the Rif(r) phenotype in prokaryotes. In addition, because of the relationship between Rif(r) and the attenuation of virulence in Brucella spp., studies of virulence in these mutants may provide useful information about the genetic basis of pathogenesis in Brucella.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.